Related Experiment Video

Updated: Aug 5, 2025

Characterizing Exon Skipping Efficiency in DMD Patient Samples in Clinical Trials of Antisense Oligonucleotides
05:16

Characterizing Exon Skipping Efficiency in DMD Patient Samples in Clinical Trials of Antisense Oligonucleotides

Published on: May 7, 2020

6.9K

A Brief Review of Duchenne Muscular Dystrophy Treatment Options, with an Emphasis on Two Novel Strategies

Ahlke Heydemann1,2, Maria Siemionow3

  • 1Department of Physiology and Biophysics, University of Illinois at Chicago, Chicago, IL 60607, USA.

Biomedicines
|March 29, 2023
PubMed

Insights

No effective treatments exist for Duchenne Muscular Dystrophy (DMD), but novel therapies show promise. Combining patient-derived chimeric cells with intraosseous transplantation effectively treated the disease in a mouse model.

Area of Science:

  • Biomedical Engineering
  • Regenerative Medicine
  • Genetics

Background:

  • Duchenne Muscular Dystrophy (DMD) remains untreatable despite decades of research following Dystrophin cDNA cloning.
  • Existing and experimental therapies for DMD have faced challenges with efficacy and severe side effects.

Purpose of the Study:

  • To review current and emerging therapies for Duchenne Muscular Dystrophy.
  • To describe a novel dual-technology approach for treating DMD in a preclinical model.

Main Methods:

  • Review of existing and pipeline DMD therapies.
  • Generation of chimeric cells from patient and donor cells.
  • Systemic transplantation of chimeric cells via the intraosseous route into the femur.

Main Results:

  • The combined novel technologies demonstrated effective treatment of DMD in the mdx mouse model.
  • Chimeric cell generation and intraosseous transplantation represent a promising therapeutic strategy.

Conclusions:

  • A combination of autologous chimeric cell generation and intraosseous transplantation offers a potential breakthrough for Duchenne Muscular Dystrophy treatment.
  • Further research and clinical trials are warranted to validate this dual-technology approach for DMD patients.
Keywords:
DECMuscular Dystrophy (MD)dystrophin expressing chimeric cellsmuscular dystrophy therapeuticssystemic-intraosseous administration

More Related Videos

Assessing Functional Performance in the Mdx Mouse Model10:32

Assessing Functional Performance in the Mdx Mouse Model

Published on: March 27, 2014

32.6K
Purification and Transplantation of Myogenic Progenitor Cell Derived Exosomes to Improve Cardiac Function in Duchenne Muscular Dystrophic Mice08:13

Purification and Transplantation of Myogenic Progenitor Cell Derived Exosomes to Improve Cardiac Function in Duchenne Muscular Dystrophic Mice

Published on: April 10, 2019

6.2K

Related Concept Videos

Satellite Stem Cells and Muscular Dystrophy01:21

Satellite Stem Cells and Muscular Dystrophy

Satellite stem cells or myosatellite cells are quiescent stem cells that Alexander Mauro first identified in 1961. These cells are located between the sarcolemma, the plasma membrane of muscle fibers, and the basal lamina, the connective tissue sheath covering it. These mononucleated cells are activated in response to muscle injury, can transform into myoblasts, and may form or repair muscle fibers. Myosatellite cells can provide additional myonuclei for muscle regeneration or return to a...
2.0K
Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
1.7K
Cystic Fibrosis: Management01:24

Cystic Fibrosis: Management

Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic...
205
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
14
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
20